DIA 49th Annual Meeting

KaloBios Pharmaceuticals

FDA fast tracks Sanofi and KaloBios' novel biologic for Pseudomonas aeruginosa

Friday, April 26, 2013 02:31 PM

The FDA has granted Fast Track designation to Sanofi Pasteur and KaloBios Pharmaceuticals’ investigational drug KB001A, an antibody fragment intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa (Pa) in mechanically-ventilated patients.

More... »


KaloBios touts phase I/II results of KB002 in persistent asthma

Thursday, February 28, 2013 08:00 AM

KaloBios Pharmaceuticals reported data from its phase I/II study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003).

More... »

CRF Health: Supporting Monitors & Investigators in Clinical Trials, April 25, May 16

KaloBios initiates phase II study with KB001-A in cystic fibrosis

Friday, January 11, 2013 12:10 PM

KaloBios Pharmaceuticals, a biopharmaceutical company based in San Francisco, Calif., has initiated dosing in a randomized, double-blind, placebo-controlled phase II clinical trial of KB001-A, the company's anti-PcrV Humaneered, PEGylated monoclonal antibody fragment. The study will investigate the safety and efficacy of intravenously administered KB001-A as a treatment for chronic Pseudomonas aeruginosa (Pa) infection in cystic fibrosis patients.

More... »

KaloBios files registration statement for proposed IPO

Friday, October 5, 2012 02:25 PM

South San Francisco-based KaloBios Pharmaceuticals has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

More... »

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

CenterWatch Medical Writing: Innovative Solutions
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.